Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Evotf source : Www.biospace.com save search
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 0.42%
H: 0.0%
C: 0.0%
partnership fibrosis
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 1.0%
H: 0.0%
C: 0.0%
year for results
Evotec welcomes Aurélie Dalbiez as Chief People Officer
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 1.0%
H: 0.0%
C: 0.0%
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: -6.81%
H: 8.65%
C: -2.23%
rare paxalisib system therapeutics
Kazia announces presentation of new data at AACR Annual Meeting
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: -0.19%
H: 11.33%
C: 8.57%
presentation meeting
Evotec SE: Invitation to Conference Call - Jan 22, 2024
Published: 2024-01-22 (Crawled : 08:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 2.11%
H: 4.69%
C: 3.88%
conference
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
Published: 2023-12-11 (Crawled : 09:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 0.82%
H: 0.92%
C: 0.92%
cell agreement platform
Kazia Therapeutics Announces $2 Million Registered Direct Offering
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: -10.83%
H: 0.0%
C: -9.8%
direct offering therapeutics
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
Published: 2023-11-15 (Crawled : 15:00) - biospace.com/
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: 18.7%
H: 0.0%
C: -12.0%
CMRX | $0.9269 1.42% 1.4% 180K
|
Health Technology
|
| O: 0.0%
H: 3.07%
C: -1.03%
pnoc022 paxalisib meeting study
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
Published: 2023-11-07 (Crawled : 08:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: -4.51%
H: 3.61%
C: 2.84%
partnership pipeline therapeutics
Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
EVOTF | $21.68 30.35% 3.2K
|
Health Technology
| Email alert
Add to watchlist
drug innovation
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
Published: 2023-08-29 (Crawled : 07:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 0.97%
H: 5.5%
C: 5.5%
results
Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
Published: 2023-08-22 (Crawled : 14:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 2.17%
H: 0.57%
C: 0.23%
results
PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens
Published: 2023-08-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
start treatment collaboration trial phase 2
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
Published: 2023-07-24 (Crawled : 14:00) - biospace.com/
SCYX | $1.53 6.25% 5.88% 150K
|
Health Technology
|
| O: -0.34%
H: 3.04%
C: -8.78%
therapeutics
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
Published: 2023-07-11 (Crawled : 08:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 3.26%
H: 1.71%
C: 1.71%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.26%
H: 0.96%
C: 0.75%
partnership agreement
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
Published: 2023-07-05 (Crawled : 11:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: 3.7%
H: 0.0%
C: -0.79%
defense contract program
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Published: 2023-06-29 (Crawled : 10:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: -2.29%
H: 0.54%
C: 0.45%
disease kidney payment milestone study
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
DAWN S | $16.65 8.26% 7.63% 6.6M
|
Professional, Scientific, and T...
|
| O: -0.69%
H: 0.0%
C: -7.55%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
KZIA | $0.369 -2.12% -2.45% 140K
|
Health Technology
|
| O: 1.57%
H: 3.07%
C: 1.53%
paxalisib therapeutics study
Evotec Presents Sustainability Strategy
Published: 2023-06-05 (Crawled : 09:00) - biospace.com/
EVO | $7.69 4.48% 4.29% 34K
|
Manufacturing
|
| O: -1.8%
H: 0.15%
C: -0.52%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.